REDHILL BIOPHAR/S (RDHL) Downgraded to Sell at ValuEngine
REDHILL BIOPHAR/S (NASDAQ:RDHL) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.
A number of other brokerages also recently issued reports on RDHL. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of REDHILL BIOPHAR/S in a report on Monday, July 2nd. Zacks Investment Research raised shares of REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Friday, October 5th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of REDHILL BIOPHAR/S in a report on Monday, June 25th. They set a “buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. REDHILL BIOPHAR/S has an average rating of “Buy” and a consensus price target of $20.80.
Shares of NASDAQ RDHL opened at $7.99 on Thursday. The stock has a market cap of $187.84 million, a PE ratio of -3.07 and a beta of 0.74. REDHILL BIOPHAR/S has a 52-week low of $4.30 and a 52-week high of $11.49.
An institutional investor recently raised its position in REDHILL BIOPHAR/S stock. ARK Investment Management LLC lifted its holdings in REDHILL BIOPHAR/S (NASDAQ:RDHL) by 8.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 112,648 shares of the biotechnology company’s stock after purchasing an additional 8,894 shares during the period. ARK Investment Management LLC owned about 0.53% of REDHILL BIOPHAR/S worth $961,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.50% of the company’s stock.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Featured Story: What is a conference call?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.